Ex­clu­sive: Degra­da­tion start­up rais­es $39M for piv­ot to PRO­TACs and clin­i­cal en­try

PAQ Ther­a­peu­tics has tak­en a new di­rec­tion.

The start­up shift­ed its pro­tein degra­da­tion ap­proach to the more com­mon PRO­TAC lane, piv­ot­ed to can­cer, hired a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER